



M K PROTEINS

Date: 14.11.2024

**To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919**

**To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai - 400051
NSE SYMBOL: MKPL**

Sub: Outcome of the Board Meeting held on 14th November 2024 pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to the Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, November 14, 2024, *inter alia*, considered and approved the Un-Audited Financial Results for the quarter and half year ended September 30, 2024 along with the Limited Review Report thereon by the Statutory Auditors of the Company.

A copy of the Un-Audited Financial Results along with Limited Review Report of the Auditors is attached herewith as Annexures.

Please note that the meeting of the Board of Directors commenced at 04:00 p.m. and concluded at 4:30 p.m.

You are requested to take the same on your record.

Thanking You,

**Yours Faithfully,
FOR M K PROTEINS LIMITED**

**Parmod Kumar
Managing Director
DIN: 00126965**

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



K R A & C O.

Chartered Accountants

☎ 011 - 47082855
Fax: 011 - 47082855

H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

Limited Review Report on Standalone Quarterly and year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To,
The Board of Directors,
M. K. Proteins Limited
Naraingarh Road, Village Garnala,
Ambala City (Haryana), India - 134003

Ref : **Limited Review Report of Unaudited Standalone Financial Results for the quarter ended 30th September, 2024 and year to date from 1st April, 2024 to 30th September, 2024**

1. We have reviewed the accompanying statement of unaudited quarterly standalone financial results of M. K. Proteins Limited ("the Company") for the quarter ended September 30, 2024 and year to date from 1st April, 2024 to 30th September, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 14th November 2024

For KRA & Co.,
Chartered Accountants
Firm Registration No. 020266N

Rajat Goyal



RAJAT GOYAL
(PARTNER)
Membership No.: 503150
UDIN: 24503150BKAMIP8472

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnaala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2024

(Rs. In Lacs)

	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	
	30-09-2024 (UNAUDITED)	30-06-2024 (UNAUDITED)	30-09-2023 (UNAUDITED)	30-09-2024 (UNAUDITED)	30-09-2023 (UNAUDITED)	31-03-2024 (AUDITED)	31-03-2023 (AUDITED)
1. Revenue							
a) Revenue from Operation (Net)	3369.01	5733.30	1364.05	9102.31	8983.56	24557.11	31486.00
b) Other Income	21.16	0.00	2.98	21.16	2.98	44.66	55.35
Sub-Total "1"	3390.17	5733.30	1367.03	9123.47	8986.54	24601.77	31541.35
2. Expenditure							
a) Cost of Material Consumed	882.10	2559.25	497.72	3441.35	3690.61	20571.80	25574.42
b) Purchase of Stock-in-Trade	430.17	407.96	880.22	838.13	2337.33	3294.36	4912.19
c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	1638.89	2156.91	(221.34)	3795.80	1886.36	(2223.11)	(1967.95)
d) Employees Benefits Expenses	62.28	65.78	67.35	128.06	136.07	278.80	177.06
e) Manufacturing, Operating and Other Expenses	131.92	169.46	76.25	301.38	469.48	973.61	1080.47
f) Finance Costs	3.32	32.82	3.64	36.14	56.01	106.49	184.16
g) Depreciation and Amortization Expenses	7.48	7.41	11.74	14.89	23.35	52.85	82.02
Sub-Total "2"	3156.16	5399.59	1315.58	8555.75	8599.21	23054.80	30042.37
3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 - 2]	234.01	333.71	51.45	567.72	387.33	1546.97	1498.98
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before Extraordinary items and Tax [3 - 4]	234.01	333.71	51.45	567.72	387.33	1546.97	1498.98
6 Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) before Tax [5 - 6]	234.01	333.71	51.45	567.72	387.33	1546.97	1498.98
8 Tax Expenses							
a) Provision for Current Tax	58.43	84.49	11.63	142.92	98.00	417.73	399.52
b) Provision for Deferred Tax Liability/(Adjustment)	1.10	1.09	(1.38)	2.19	(0.92)	8.05	6.00
c) Prior Year Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sub-Total "8"	59.53	85.58	10.25	145.11	97.08	425.78	405.52
9 Profit/(Loss) for the Period from continuing operations [7 - 8]	174.48	248.13	41.20	422.61	290.25	1121.19	1093.46
10 Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11 Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from Discontinuing operations (After Tax) [10 - 11]	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13 Profit/(Loss) for the period [9 + 12]	174.48	248.13	41.20	422.61	290.25	1121.19	1093.46
14 Other Comprehensive Income net of taxes							
a) (i) Amount of items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	(0.55)	0.79
(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	(0.14)	0.20
b) (i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sub- Total "14"	0.00	0.00	0.00	0.00	0.00	(0.41)	0.59
15 Total comprehensive Income for the Period [13 + 14]	174.48	248.13	41.20	422.61	290.25	1120.78	1094.05

16	Earnings per share							
a)	Earnings per Equity Share for continuing operations							
	Basic earnings/(Loss) per share from continuing operations	0.04	0.07	0.33	0.11	2.32	0.30	8.74
	Diluted earning/(Loss) per share from continuing operations	0.04	0.07	0.33	0.11	2.32	0.30	8.74
b)	Earnings per Equity Share for discontinuing operations							
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share							
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.04	0.07	0.33	0.11	2.32	0.30	8.74
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.04	0.07	0.33	0.11	2.32	0.30	8.74
17	Details of Equity Share Capital							
	Paid-up Equity Share Capital	3753.72	3753.72	1251.24	3753.72	1251.24	3753.72	1251.24
	Face value of Equity Share Capital	1	1	10	1	10	1	10
18	Other Equity [Reserves]	-	-	-	2776.45	4066.19	2353.84	3735.19

Note:

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14th November, 2024.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015.
4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
5. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 2024 is given as per Annexure "I" attached

Place: Ambala

Dated: 14-11-2024

For and on behalf of the board

(Parmod Kumar)
Managing Director
DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garmala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01013


ANNEXURE "I"

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2024 IS GIVEN BELOW: -

	PARTICULARS	AS AT	AS AT	AS AT
		30-09-2024	30-09-2023	31-03-2024
		(UNAUDITED)	(UNAUDITED)	(AUDITED)
A	ASSETS			
1	Non-Current Assets			
	-Property, Plant and Equipment	178.48	212.94	189.69
	-Capital Work-in-Progress	590.00	0.00	590.00
	-Right of Use Assets	85.38	0.00	87.51
	-Intangible assets	0.00	0.00	0.00
	Financial Assets			
	-Investments	0.00	0.00	0.00
	-Other financial assets	34.28	42.35	44.50
	Deferred Tax Assets (net)	35.27	34.65	37.46
	Other non-current assets	91.34	44.64	91.34
	Sub-Total "1" Non-Current Assets	1014.75	334.58	1040.50
2	Current Assets			
	-Inventories	3397.07	3187.26	7927.25
	Financial Assets			
	-Investments	1956.16	297.98	0.00
	-Trade Receivables	51.81	2896.22	357.27
	-Cash and Cash Equivalents	11.47	10.92	9.23
	-Other Financial assets	0.00	0.00	0.00
	Other Current Assets	675.05	61.27	290.35
	Sub-Total "2" Current Assets	6091.56	6453.65	8584.41
	TOTAL ASSETS	7106.31	6788.23	9624.60
B	EQUITY AND LIABILITIES			
1	Equity			
	-Equity Share Capital	3753.72	1251.24	3753.72
	-Other Equity	2776.45	4066.19	2353.84
	Sub-Total "1" Total of Equity	6530.17	5317.43	6107.56
2	Liabilities			
	Non-Current Liabilities			
	Financial Liabilities			
	-Borrowings	0.00	0.00	0.00
	-Lease Liabilities	95.96	0.00	97.19
	-Other financial liabilities	0.00	0.00	0.00
	Provisions	24.08	9.89	23.61
	Other non-current liabilities	0.00	0.00	0.00
	Sub-Total Non-Current Liabilities	120.04	9.89	120.80
	Current Liabilities			
	Financial Liabilities			
	-Borrowings	34.94	730.13	1909.06
	-Lease Liabilities	2.28	0.00	2.07
	-Trade Payables	311.29	592.29	1148.84
	-Other Financial Liabilities	0.38	11.17	30.23
	Other Current Liabilities	42.68	91.65	80.99
	Provisions	2.87	0.00	2.87
	Current Tax Liabilities (Net)	61.66	35.67	222.18
	Sub-Total Current Liabilities	456.10	1460.91	3396.24
	TOTAL EQUITY AND LIABILITIES	7106.31	6788.23	9624.60

Place: Ambala
Dated: 14-11-2024

For and on behalf of the board


 (Parmod Kumar)
 Managing Director
 DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Gamala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2024

	PARTICULARS	FOR THE HALF YEAR ENDED 30/09/2024 UNAUDITED	FOR THE HALF YEAR ENDED 30/09/2023 UNAUDITED	FOR THE YEAR ENDED 31/03/2024 AUDITED
A.	CASH FLOW FROM OPERATING ACTIVITIES			
	-Net Profit/(Loss) before tax	567.72	387.33	1546.97
	-Adjustment for:-			
	Depreciation and amortisation expenses	14.89	23.35	52.85
	Interest Expenses	36.14	56.01	106.49
	Provision of allowances for Bad and Doubtful debts (Excepted credit loss allowance)	0.00	0.00	(33.32)
	Provision for Retirement Gratuity Benefit to Employees	0.00	0.00	3.57
	Net Gain on Sale/Fair Valuation of Investment on FVTPL	(21.16)	(2.98)	(3.62)
	Interest Income	0.00	0.00	(1.03)
	Operating profit before working capital changes	597.59	463.71	1671.91
	Adjustment for (Increase)/Decrease in operating assets:			
	-Trade Receivables	305.47	(1255.55)	1281.61
	-Inventories	4530.17	3933.23	(806.75)
	-Other Non-Current Assets	0.00	0.00	(44.98)
	-Other Current Assets	(384.71)	1064.60	835.52
	Adjustment for Increase/(Decrease) in operating Liabilities:			
	-Trade Payables	(837.55)	112.05	668.60
	-Other Financial Current liabilities	(29.85)	(27.26)	(8.20)
	-Other Current Liabilities	(38.30)	5.89	(4.77)
	-Provisions	0.00	0.00	0.00
	Cash use in / generated from operation	4142.82	4296.67	3592.94
	-Direct taxes paid	(303.43)	(218.44)	(351.32)
	NET CASH FROM OPERATING ACTIVITIES	3839.39	4078.23	3241.62
B.	CASH FLOW FROM INVESTING ACTIVITIES			
	-Sale Proceed of fixed assets	0.00	0.00	0.00
	-Sale Proceeds for Investment in Mutual Funds	0.00	0.00	298.62
	-(Increase)/Decrease in Bank Balances not considered as Cash and Cash Equivalent	0.00	0.00	0.00
	-Purchase of Investment	(1935.00)	(295.00)	(295.00)
	-Fixed Assets /Capital Work-in-progress Purchases	(1.55)	(0.33)	(590.33)
	-Other Non-Current Financial Assets (Securities)	10.22	0.00	(2.15)
	-Interest Income	0.00	0.00	1.03
	NET CASH FROM INVESTING ACTIVITIES	(1926.33)	(295.33)	(587.83)

C. CASH FLOW FROM FINANCING ACTIVITIES				
-Increase/(Decrease) in Short term Bank Borrowings		(1870.20)	(3466.46)	(2281.82)
-Increase in Long Term Borrowings		0.00	0.00	0.00
-Payment of Lease Liabilities		(6.00)	0.00	(12.00)
-Repayment of long term borrowings		(3.92)	(255.76)	(261.47)
-Finance cost		(30.70)	(56.01)	(95.52)
NET CASH FROM FINANCING ACTIVITIES		(1910.82)	(3778.23)	(2650.81)
NET CASH FLOW DURING THE YEAR (A+B+C)		2.24	4.67	2.98
Cash and Cash Equivalent at beginning of the period		9.23	6.25	6.25
Cash and Cash Equivalent at end of the period		11.47	10.92	9.23

Place: Ambala

Dated: 14-11-2024

For and on behalf of the board


(Parmod Kumar)
Managing Director
DIN: 00126965